NASDAQ:OPTN - OptiNose Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OptiNose Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.47 +0.24 (+2.92 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$8.09Now: $8.47▼$8.5450-Day Range$7.26MA: $8.97▼$11.0752-Week Range$4.44Now: $8.47▼$11.66Volume264,491 shsAverage Volume212,772 shsMarket Capitalization$352.20 millionP/E RatioN/ADividend YieldN/ABeta0.74 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPTN Previous Symbol CUSIPN/A CIK1494650 Webhttp://www.optinose.com/ Phone267-364-3500Debt Debt-to-Equity Ratio1.67 Current Ratio4.81 Quick Ratio4.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.07 million Price / Sales49.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book2.94Profitability EPS (Most Recent Fiscal Year)($2.68) Net Income$-106,660,000.00 Net Margins-419.37% Return on Equity-137.60% Return on Assets-61.40%Miscellaneous Employees102 Outstanding Shares41,582,000Market Cap$352.20 million Next Earnings Date3/4/2020 (Estimated) OptionableNot Optionable Receive OPTN News and Ratings via Email Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OPTN Rates by TradingView OptiNose (NASDAQ:OPTN) Frequently Asked Questions What is OptiNose's stock symbol? OptiNose trades on the NASDAQ under the ticker symbol "OPTN." How were OptiNose's earnings last quarter? OptiNose Inc (NASDAQ:OPTN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.69). The business had revenue of $12.40 million for the quarter, compared to the consensus estimate of $8.56 million. OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. View OptiNose's Earnings History. When is OptiNose's next earnings date? OptiNose is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for OptiNose. What price target have analysts set for OPTN? 4 Wall Street analysts have issued twelve-month target prices for OptiNose's stock. Their forecasts range from $20.00 to $29.00. On average, they expect OptiNose's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 195.2% from the stock's current price. View Analyst Price Targets for OptiNose. What is the consensus analysts' recommendation for OptiNose? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose. What are Wall Street analysts saying about OptiNose stock? Here are some recent quotes from research analysts about OptiNose stock: 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (11/16/2019) 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our OW rating and $27 12- month PT for OPTN. Despite a lumpy Xhance initial launch, we believe we are beginning to see Xhance gain traction, which supports our confidence in the peak sales potential of the product. In 2019, we believe the increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year, and beyond. OPTN has evolved aspects of its launch strategy, which we view as positive and believe are beginning to pay dividends. We continue to take a conservative approach to Xhance revenue in 2019 while the updated launch strategy is fully implemented." (5/9/2019) Has OptiNose been receiving favorable news coverage? News coverage about OPTN stock has trended extremely negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OptiNose earned a news sentiment score of -4.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future. View News Stories for OptiNose. Who are some of OptiNose's key competitors? Some companies that are related to OptiNose include Nabriva Therapeutics (NBRV), Athenex (ATNX), Esperion Therapeutics (ESPR), Innoviva (INVA), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Principia Biopharma (PRNB), ArQule (ARQL), NextCure (NXTC), Rocket Pharmaceuticals (RCKT) and Wave Life Sciences (WVE). What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Syndax Pharmaceuticals (SNDX), Coherus Biosciences (CHRS), Clearside Biomedical (CLSD), Arcos Dorados (ARCO), Resonant (RESN), OrganiGram (OGI), SVB Financial Group (SIVB) and Stemline Therapeutics (STML). Who are OptiNose's key executives? OptiNose's management team includes the folowing people: Mr. Peter K. Miller, CEO & Director (Age 58)Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)Mr. Thomas E. Gibbs, Exec. VP & Chief Commercial Officer (Age 47) When did OptiNose IPO? (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. Who are OptiNose's major shareholders? OptiNose's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (3.33%), Massachusetts Financial Services Co. MA (2.49%), Tamarack Advisers LP (1.63%), Kornitzer Capital Management Inc. KS (1.31%), Wildcat Capital Management LLC (1.25%) and State Street Corp (1.05%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose. Which major investors are selling OptiNose stock? OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Rice Hall James & Associates LLC and Barclays PLC. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp, and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose. Which major investors are buying OptiNose stock? OPTN stock was purchased by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Wildcat Capital Management LLC, Massachusetts Financial Services Co. MA, Millennium Management LLC, State Street Corp, Tower Research Capital LLC TRC and Squarepoint Ops LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose. How do I buy shares of OptiNose? Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is OptiNose's stock price today? One share of OPTN stock can currently be purchased for approximately $8.47. How big of a company is OptiNose? OptiNose has a market capitalization of $352.20 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose. What is OptiNose's official website? The official website for OptiNose is http://www.optinose.com/. How can I contact OptiNose? OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected] MarketBeat Community Rating for OptiNose (NASDAQ OPTN)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 194 (Vote Outperform)Underperform Votes: 218 (Vote Underperform)Total Votes: 412MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: How can investors benefit from after-hours trading?
